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Vascular disease is a major cause of ;.lorbidity and mortality in 
patients with diabetes mellitus (1). Atherosckrosis. resulting in 
myocardial infarction, stroke and ischemic extremities. is much 
more frequent in diabetic than nondiabetic population5 (1). 
Furthermore. small-vessel disease, resulting in diabetic reti- 
tqtathy and nephropathy, also contributes importantly to the 
morbidity associated with this disease (2). 
Decreased availability of endothelium-derived nitric oxide 
may contribute to vascular disease in diabetes. Nitric oxide is a 
potent vascdilator released by the endothelium which pIa a 
- -- 
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pivotal r& in maintaining vascular homeostasis (.3-6). Nitric 
oxide has been shown to inhibit platelet aggregation (7). 
prdiferahon d vascular smooth musck (8) and kukocyte 
adksion to the vascular wall (9). Decreased rekasc or activity 
of nitric oxide could contribute to abanmalitks d vaxnmtor 
function as well as to atherogencsis through kss d these 
protective prllpertk 
There is now substantial evidence ihat endothelium- 
deyendent vawdiition is abnormal in animal models of 
diabetes mellitus (10-18). We and others have demonstrated 
that endothelium-&pe&a vaso&tioa is impaued in pa 
tientswithirsulm-depcndcntdiabetamellitusprob&lyasa 
resultofthedccrca&availabilitydendothcliaJnitticoxidc 
(19-21). MeVeigh ei al. (22) reported that patients with 
. . 
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Table I. Characteristics of the Study Paticntq 
Diahclic Suhjccl* <‘ontrol Subjcch 
(II !I) (fl - 23) 
4e (8’) u+2 41 z 1 
Female,male 1 I-l 617 
Smoker (y:sino) 5.16 J 19 
Mean blood preswc (mm Hg) Y! 2 ? x7 t z 
BoQ ma- mdcn (k&m’) 29 z I 3: I’ 
Totar cholesterol (mgdl) IX9 z h 17526 
HDL cholesterol (mgidl) 41 z z 4x23 
LDL cholesrcrol (mydl) I?? z s Ilb2-l 
Triglycerides (mgdl) I87 z 15 III 2 II’ 
Glucose (mg’dl) 19.5 z I-l us z 3 
Glycosylatcd hcmoglohin (5) Ilr I s c 11.4: 
Insulin tmU:ml) -ill f x I? t 1: 
Blood urea nitrogen (mgdl) IS ? I 15 f I 
Crcatinine (mgidl) I, I z II.07 1.1 f 0.t13 
‘p < 11.05. tp c 11.(101. Data prescntcd arc mean value : SD or numtw of 
subjects. HDL = high density lipoprotein: LDL = !ou denwy lipoprolcin. 
tal models of diabetes mellitus (24). has not yet been assessed 
in diabetic humans. For these reasons, the mechanisms of 
vascular dysfunction in non-insulin-dependent diabetes re- 
mains unclear. 
AccordinJy, the overall objective of this study was to 
determin: whether vasodilator reactivity is abnormal in 
patients with non-insulin-dependent diabetes mellitus. Fur- 
thermore, we sought to determine whether the mrchanisms 
responsible for vascular dysfunction are confined to abnorrnal- 
tties in the nitric oxide pathway. to increased release of 
vasoconstrictor prostanoids that counteract nitric oxide- 
mediated vasodilation or to generalized impairment of vascu- 
lar smooth muscle. 
Methods 
Subjects. The study group included 21 subjects with non- 
insulin-dependent diabetes mellitus and 23 healthy control 
subjects (Table 1). The two groups were closely matched with 
respect to age. The average duration of diabetes was 4 years 
(range 6 months to 12 years). Glycemic control was achieved 
by diet alone (n = 2), by diet plus sulfonylurea (n = 18) or by 
diet plus daily insulin injections (n = I). The patient receiving 
insulin met criteria for classification as non-insulin-dependent 
diabetes since he had previously achieved adequate control of 
hyperglycemia with diet and sulfonylurea and had never had 
diabetic ketoacidosis. Subjects were recruited from the Boston 
area by advertisements in focal newspapers. All subjects un- 
derwent a screening that included medical history, physical 
examination, electrocardiogram (ECG) and laboratory testing, 
including complete blood count, serum electro@es, blood 
glucose, insulin, -ted hemogkGn, serum transami- 
nases, blood urea nitrogen and serum crcatinine. The criteria 
fiw exclusion of both diabetic and healthy volunteers included 
hypertemion (>145‘!IO mm Hg), ekvated law density l@pro- 
tein (LDL) cholesterol ccmcentration (>75th percentile for 
age and gender), cardiac or pulmonary disease or use of any 
antihypcrtensive. crdiac or vasoactive medication. No subject 
had overt evident: of atherosclerosis as judged by the absence 
of symptoms of angina. claudication or cerebrovascular isch- 
emia. and each had a normal vascular examination, including 
normal pulses and absence of bruits. The protocol was ap 
proved by the Committee for the Protection of Human Sub- 
jects of the Brigham and Women’s Hospital. and each volun- 
teer gave written informed consent. 
Experimental protocol 1: assesswent of nitric oxide- 
mediated vasodilatinn. All participants (21 diabetic subjects, 
23 nondiabetic control subjects) received 325 mg of acetylsal- 
icylic acid daily for 3 days (including the day of the study) to 
eliminate the confounding effects of vasoactive prostanoids in 
the evaluation of endothelium-dependent vasodilation (25). 
Each subject was studied the morning after an overnight fast. 
Alcohol, calfeine, cigarettes and use of any medications (in- 
cluding insulin or oral hypoglycemic agents) were prohibited 
within 12 hours of the study. Under local anesthesia and sterile 
conditions, a 20-gauge Teflon catheter was inserted into the 
brachial artery of each ‘ubject for determination of blood 
pressure and infusion o! drugs. Blood samples were obtained 
for serum glucose, gfycosylated hemoglobin, serum insulin and 
lipid profile. The vascular research laboratory was noise free; 
the lights were dimmed; and room temperature was controlled 
at 23°C. Ah subjects rested for a minimum of 30 min after 
catheter placement and before data acquisition to establish a 
stable baseline. 
Measurements of basal forearm blood flow and blood 
pressure were repeated every IO min until stable. To determine 
the maximal vasodilator potential of the resistance vessels 
forearm blood flow was measured during reactive hyperemia 
induced by inflation of a sphygmomanometric cuff on the 
upper arm to suprasystolic pressure for 5 min. Abnormalities 
in peak reactive hyperemic blood flow are indicative of struc- 
tural defects in the resistance vessels, preventing maximal 
vasodilation. 
Methacholine chloride (Roche Laboratories) was adminis- 
tered through the brachial artery cannula to all participants to 
assess vasodilation to endotheliumderived nitric oxide. In 
preliminary experiments, we found that the nitric oxide syn- 
thase inhibitor Nc’-monomethyl-L-arginine significantly atten- 
uated the vasodilator response to methacholine chloride, pro- 
viding direct evidence for methacholine-induced release of 
endotheliumderived nitric oxide. Forearm blood flow was 
measured during infusion of increasing concentrations of 
methacholine chloride at doses of 03. 1, 3 and 10 &min. 
Sodium nitroprukk (Elkins-Sinn Inc.) was infused in all 
subjects to assess the response of the vascular smooth muscle 
to an exogenous nitric oxide donor. This direct-acting nitric 
oxide donor, which releases nitric oxide in situ, was adminis- 
tered in doses of 0.3,l. 3 and 10 &nin. The cakium channel 
blocking agent verapamil (American Reagent L&ratory Inc.) 
was used as an endothelium-independent and nitric oxide- 
independent vawdilatof to examine the po6siiity that abnw 
malitiiofvasodilationarenntamfinedtotknitricoxide- 
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guanylate cyclase pathway. and instead represent a generalized 
impairment of vascular smooth muscle. Data in support of the 
use of verapamil as a nitric oxide-independent agent comes 
from experiments in our laboratory demonstrating that the 
forearm blood flow response to verapamil was not signiticantly 
attenuated by the concomitant administration of hG- 
monomethyl-L-arginine (26). Verapamil was administered at 
doses of 10, 30. 100 and 300 lLglmin in I8 of the 21 diabetrc 
subjects and 20 of the 23 nondiabetic control subjects. 
The range of doses for each drug was chosen to achieve a 
maximal change in forearm blond flow and forearm vascular 
resistance without concomitant systemic effects (19). Baseline 
infusii of vehicle (5% dextrose) and of drug (diluted in 5% 
dextrose) were administered at 0.4 ml/min. Hemodynamic 
measurements were performed after each drug dose had horn 
delivered for 3 mm-the shortest time for steady state effect as 
determined from previous studies (19). Basal conditions were 
reestablished between each intervention after waiting a mini- 
mum of 30 min for the previous drug to clear. 
E!qteIimemw pNtocol2 assessment of he role of vasu- 
~rw&mrW To gain insight iato the effect of 
vasoarnstrictor prostanoids on the vascular function in non- 
insulindependent diabetes, a subgroup of eight diabetic sub 
jects chosen at random were reexamined in the absence of 
acetylsalicylic acid. All cyclooxygenase inhibitors were pmhib 
ited 1 week before examination. All other aspects of the 
protocol were identical to that outlined above. 
Hemodyu&c mreamts. Bilateral forearm blood 
Row was determined by venous occlusion mercury-in-Silastic 
strain-gauge plethysmography (Hokanson EC4. DE Hokan- 
son) (in ml blood/min per 100 ml tissue) (27). Both arms were 
suspended above the level of the heart to allow sutlicient 
venous return. Venous occlusion pressure averaged 36 t 
I mm Hg (mean + SE). To ensure that blood flow measure- 
ments referred predominantly to the vasculature suppfying 
muscular tissue, hand circulation was occluded by inflating a 
wrist cuff to suprasystolic pressures during each measurement 
interval (28). The foreamt blood flow measurements ccnn- 
prised a minimum of five separate measurements performed at 
IO- to 15-s intervals. The blood Row measurements in the 
inhrsed study arm allowed determination of the response to the 
drugs. whereas measurements in the contralateral arm verified 
that these agents were not causing systemic effects Forearm 
vascular resistance was calculated as the ratio of mean blood 
pressure to forearm bbood flow and is expressed in arbitrary 
units (AU). 
Blood pressure was measured by means of the arterial 
cannub. which *as attached to a Statham P23 pressure 
transducer aligned to an amplifier on a Gould physiologic 
recorder (Gould Inc.). Heart rate was determined from a 
sirnultaneo&yobtaiwdECGandwascakulatedfmrntheRR 
inkM1 
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Fire 1. Baseline and reactive hyperemic forearm blood flow in 
dish-tic and nondiahetic subject No statistical ditTerence was seen 
hetw;rn diabetic and nondiabetic &jects for baseline blood Roar (p > 
11.10) and reactive hyperemic response (p > 0.20). as analyze by 
unpaired I test. 
appropriate. Statistical analyses of rhe dose-response curves 
for each drug (methacholine chlorio:. sodium nitroprusside 
anJ verapamil) were conducted for the changes from baseline 
(to control for baseline variability). Two-way repeated- 
measures analysis of variant, (,!rUOV.i) was performed to 
compare the dose-response curves between the two groups. 
Although only the results of the repeated-measures ANOVA 
are reported comparisons of the slopes of the dose-respome 
cures between groups gave similar results. The Bonferroni 
correction for multiple testing was used to test the differing 
response between diabetic and mmdiabetic subjects to each 
drug dose (29). Univariate linear rep& analyses were 
performed to correlate the vasodilator response of each drug 
to selected variables. Statistical significance was accepted at 
the 95% confidence level (p I 0.05). 
Rt!SOltS 
lkdimenkrsaf~~ Thebaselinecharacterks- 
ticsofthediabeticandnon&beticshrdygmupsareprovi&d 
in TaMP 1. Age, gender and smoking status were matchul 
between groups. No patient in either group had hypenelsioa 
and mean arterial pressure was not statistically diRerent be- 
tween groups Diabetic &jects had elevated body mass index 
relative to control subjects (p < 0.05). There was no diRerence 
in total, high density @protein (HDL) or LDL cbdesterd 
betweendiabeticandooadi&etic~However,&betic 
suhje43 did have elmted tridyccride kveb (p < 0.05). Ar 
expeaed. sc?.rm ghtco5e. glyeo@ated hemogWn and insulin 
kvekwrcrralls@i8caatlyhigberindi&eticthannondipbttic 
subjects (p -c 0.001 for each). Renal function as amessed by 
bbodureanitrogenandserumcreatinine.wascanpinble 
betwcenthetwoBarps. 
I?berewasatrendtow?rdahi@erbi&ineforunnMmd 
euwintiideicsubjeus(Ls’03~per100ml)tk8ll 
ltoo&h&suhjeas(23~02mvminper100d~tmt~ 
dihmcc wa wt stdidy sigdcmt (p > 0.10) (F+ I). 
nleaJrrqd@tmelinefalaumvasadar-was 
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Figure 2. Forearm blood RW increase from baseline during graded 
intraarterial infusion of methacholine chloride in diabetic and nondi- 
abetic subjects. The response to methacholine chloride was signifi- 
cantly attenuated in diabetic compared with nondiahetic subjects. as 
analyzed by repeated-measures analysis of variance (p < 0.005). The 
difference behveen groups ws significant at three of the four doses by 
the Bonferroni correction for multiple comparisons (‘p < 0.05). 
38 k 3 AU in diabetic and 45 -C 4 AU in control subjects (p > 
0.10). 
Forearm blood flow response to metbacholiw chloride. 
Intraarterial infusion of methacholine chloride increased fore- 
arm blood flow in both diabetic and nondiabetic subjects (Fig. 
2). However, the vasodilator response to methacholine was 
significantly attenuated in diabetic compared with nondiabetic 
subjects (p < 0.005 by ANOVA). At the highest dose of 
methacholine (10 Ccg/min), forearm blood flow increased only 
6.4 2 0.9 ml/min per 100 ml in diabetic comrsred with 10.1 % 
1 ml/min per 100 ml in nondiabetic subjects (p < 0.05. 
Bonferroni correction for multiple comparisons). Similarly, the 
corresponding decreases in forearm vascular resistance in 
response to methacholine infusion were attenuated in diabetic 
compared with nondiabetic subjects (p < 0.05, ANOVA); at 
the highest dose of mcthacholine, forearm vascular resistance 
decreased only 26 ? 3 AU from baseline in diabetic compared 
with 37 ? 4 AU in control subjects (p < 0.05, Ekmferroni 
correction). 
There were no systemic effects of the mcthacholine infusion 
in either group; the infusion did not change contralatera! 
forearm blood flow, and there was no change in mean arterial 
pressure or heart rate during drug administration. 
Forearm blood Row response to sodium q itroprusside. 
Sodium nitropntsside also increased forearm blood flow in 
both diabetic and nondiabetic subjects (Fig. 3). However, the 
vasodilator response to nitroprusside was significantly artenu- 
ated in diabetic compared with nondiabetic subjects (p < 
0.005, ANOVA). At the highest dose of nitroprusside 
(10 &min), forearm blood flow increased only 4.6 2 
0.6 mUmin per 100 ml in diabetic compared with 8.4 2 
1 mUmin per 100 ml in control subjects (p < 0.005, Bonferroni 
correction). When expressed as forearm vascular resistance, 
the data demonstrate an impaired response to nitroprusside in 
diabetic relative to control subjects (p < 0.05, ANOVA); at the 
--z- 0.3 1.0 3.0 10.0 
Sodium NltropruGde (w&b 
Figure 3. Forearm blood flow increase from baseline during graded 
intraarterial infusion of sodium nitropmsside in diabetic and nondia- 
betic subjects. The response to sodium nitropmsside was signikantly 
attenuated in diabetic compared with nondiabetic subjects, as analyzed 
by repeated-measures analysis of variance (p C 0.005). The difference 
between groups was significant at the 3.W ( l p < 0.05) and 10.~&min 
doses (**p < O.t!4!5). 
higher.t dose of nitroprusside, forearm vascular resistance 
decreased only 21 t 2 AU from baseline in diabetic compared 
with 3.? 2 4 AU in nondiabetic subjects (p < 0.05, Bonfennni 
correcilon). 
Infusion of sod:um n’koprusside did not affect forearm 
blood flow in the contralrteral arm in either group, and there 
was no significant change in blood pressure or heart rate 
during drug administration. 
Forearm blood flow response to verapamil. Verapamil 
increased forearm blood flow and decreased forearm vascular 
resistance in both diabetic and nondiabetic subjects (Fig. 4). In 
contrast to the findings with methacholine and nitroprusside, 
the vasodilator response to verapamil was not statistically 
different between the groups (p > 0.50, ANOVA). At the 
maximal dose of verapamil (300 &min), the increase in 
forearm blood flow was similar between the two groups (6.9 ? 
1.0 vs. 8.0 I? 0.9 ml/min per 100 ml in diabetic and nondiabetic 
Figure 4. Forearm blood flow increase from baseline during graded 
intraarterial infusion of verapamil in diabetic and nondiabetic subjects. 
r*‘d signitkant difference was seen between diabetic and nondiabetic 
subjects in the response to verapamil, as analyzed by repeated- 
measures analysis of variance (p > 0.50). 
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subjects, respectively). Similarly. the decline in forearm vascu- 
lar resistance was not +Iificantly different between groups 
(p > 0.40. ANOVA); the decrease in forearm vascular rcsis- 
tancc at the highest dose was 26 2 2 AU in diabetic versus 
29 2 2 AU in nondiabetic subjects. 
Forearm blood flow did not increase in the contralateral 
arm in either group during infusion of verapamil. Also. there 
was no change in blood pressure or heart rate during drug 
administration. 
Reactive hyperemie foream~ blood Row. Reactive hypere- 
mic blood flow is illustrated in Figure 1. The peak reactive 
hyperemic blood flow was similar in diabetic subjects (19.6 2 
1.2 ml/min per 100 ml) and nondiabetic subjects (22.1 + 
I.5 ml/min per 100 ml. p > 0.20). Similarly. minimal vascular 
resistance (calculated as the ratio of the baseline mean arterial 
pressure to peak reactive hyperemic blood flow) was not 
statistically different between the groups (5.1 z 0.4 in diabetic 
vs. 4.3 ? 0.3 in nondiabetic subjects, p > 0.10). 
Relation ofvasodilator rqonsc to clinical variables. In an 
attempt to gain insight into the biochemical mechanism or 
mechanisms by which the diabetic state leads to altered 
vascular function in non-insulin-dependent diabetes, univari- 
ate linear regression analyses were performed on data derived 
from the diabetic subjects. In this analysis, each of the putative 
markers of diabetes were correlated with the slope of !he 
dose-response to both methacholine and nitroprusside. There 
was no significant correlation between the vasodilator response 
to either methacholine or nitroprusside and the following 
clinical variables: serum glucose, glycosylated hemoglobin. 
serum insulin, weight, body mass index. duration of diabetes, 
total cholesterol, LDL cholesterol, HDL cholesterol or triglyc- 
eride concentration. 
Subset analyses were performed to determine whether body 
mass index or triglyceride concentration (which differed be- 
tween the diabetic and nondiabetic groups) could account for 
the observed difference in vascular function between the 
groups. Obese patients with diabetes (>95th percentile body 
mass index for gender and age, n = 5) were excluded, and the 
vasodilator responses of the remaining nonobese diabetic 
subjects were compared with those of the nondiabetic subjects. 
There was no significant difference in either body mass index 
or weight between these subgroups, yet the findings of the 
study were not altered (p C 0.03 and p C 0.01 between groups 
for methacholine and nitroprusside. respectively. whereas the 
responses to veqamil were not significantly different, p > 
0.60). A similar subset analysis was performed by excluding the 
hypertriglyceridemics (>95tb percentile for gender and age, 
n = 4) to evaluate the possibility of hypertriglyceridemia in the 
diabetic patients as a potential confounder in this study. 
Excluding hypertriglyceridemic subjects also did not after the 
findings of the study (p C 0.01 between groups for both 
methacholine and nitroprusside. whereas the nqonses to 
verapamil were not significantly different, p > 0.60). Finally, 
excluding the patient who was receiving exogenous insulin 
therapy dii not alter the findings of the study (p C 0.01 
between groups for both rnethacholine and nitroprusside, 
Figure 5. Forearm blood flow increase from baseline in diabetic 
subjects during graded intraarterial infusion of methacholine chloride 
in the presence and absence of cyclooxygenase inhibition by acetykal- 
icylic acid. There was no significant effect of cyclooxygenase inhibition 
on the responses to methacholine. as analyzed by repeated-measures 
analysis of variance (p > 0.80). 
whereas the responses to verapamil were not significantly 
di5erent between groups. p > 0.50). 
Assessmefit of role of viawm&Mor prostaaoids. Base- 
line blood flow was similar in diabetic sub@ts in the presence 
and absence of acetylsalicylic acid (2.8 % 0.5 ys. 2.5 1 
0.5 ml/min per IO0 ml. p > 0.20). The reactive hyperemic 
response also was similar before and during acetykalicyiic acid 
(17 ? 1 vs. 19 + 2 ml/min per 100 ml, respectively, p > 0.40). 
The vasodilator response to methacholine was not significantly 
affected by the presence or absence of acetylsaliqlic acid (p > 
0.80, ANOVA) (Fig. 5). Similarly, the responses to nitroprus- 
side (p > 0.30, ANOVA) and verapamil (p > 0.80, ANOVA) 
were unaffected by qciooxygef.ase inhibition. 
Discussion 
The salient information derived from these experiments is 
that nitric oxide-mediated vasodilation is abnormal in patients 
with non-insulin-dependent diabetes meltitus. The attenuated 
response to both methacholine and nitropru.sside in non- 
insulin-dependent diabetic subjects compared with that in 
nondiabetic subjects indicates impaired vasodilation to both 
endogenous and direct-acting exogenous nitric oxide donors. 
The observation that the responses to both verapamil and 
reactive hyperemia were similar in diabetic and nondiabetic 
subjects suggests that the functional integrity of the. vascular 
smooth muscle is not compromised iu non-insulin-dependent 
diabetes. Furthermore, the finding that qclooxygenase inhibi- 
tion had no effect on the response to any of these vwactive 
agent3 eliminates increased vasoconstrictor pr&anoid release 
astheetiologyofdiabeticvaaodilatordysfunction 
EVidWNVdeddMld djdm&nbdiab&esmteJlha 
Evidence for endothelial dysfunction in diabetes mefiitus 
comes in large part, from animal m&k of diabetes (10-18). 
Obsematio~~~ in patiemtswitb insulikdependent diabetes ml- 
lituscon&oratethefindingsinanimalmodekWeprev&+ 
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reported (19) that patients with insulin-dependent diabetes 
have an attenuated forearm vasodilator response Lo mcthacho- 
line compared with matched healthy subjects. In that study. WC 
also demonstrated normal vasodilation to the exogenous nitric 
oxide donor nitroprusside and lo the calcium channel blocker 
verapamil. The work of Calver et al. (20) and Elliott et al. (21) 
complements our findings in insulin-dependent diabetes mel- 
litus. They found that the vasoconstrictor response to the nitric 
oxide synthase antagonist P-monomethyl+-arginine is re- 
duced in insulin-dependent diabetes, implicating impaired 
basal release of nitric oxide from the endothelium. In coa.rsst. 
Halkin et al. (30) and Smits et al. (31) did not observe a defect in 
endotheliumdependent vasodilation in patients with insulin- 
dependent diabetes. Both of these latter studies included detect- 
able microalbuminuria as an exclusion criterion for their diabetic 
population. the presence of which correlates with the severity of 
endothelial dysfunction (21). Despite the inconsistency of the 
data, however, it is clear that the vasodilator defect in insulin- 
dependent diabetes. when detected, involves endothelium- 
derived nitric oxide. 
In our study. patients with non-insulin-dependent diabetes 
exhibited an attenuated response to both endothelium-derived 
nitric oxide (released in response to methacholine), as well as 
to the direct-acting exogenous nitric oxide donor nitroprusside. 
These results are consistent with the report by McVeigh et al. 
(22), who demonstrated impaired vasodilation lo both acetyl- 
choline and glyceryl trinitrate in non-insulin-dependent dia- 
betic subjects relative to control subjects. However, in inter- 
preting the abnormal response to glyceryl trinitrate, McVeigh 
et al. concluded that this unexpected finding was due to 
nitroglycerin tolerance in the diabetic patients, and they spec- 
ulated that the response to a direct-acting nitric oxide donor 
(such as nitroprusside) would not be attenuated (23). Our data 
refute this hypothesis, confirm the impaired response to exog- 
enous nitric oxide donors, and thus indicate that the vascular 
defect in non-insulin-dependent diabetes mellitus cannot be 
attributed solely to abnormal endothelial production of nitric 
oxide. Furthermore, the demonstration of normal nitric oxide- 
independent vasodilation in our protocol (as assessed by 
verapamil) eliminates the possibility that the vascular abnor- 
mality is simpry due to generalized impairment of vascular 
smooth muscle, and instead isolates the impairment to the 
nitric oxide pathway. 
Mechanisms of vascular dysftmctbn in diabetic Patients. 
Several potential mechanisms have been proposed to explain 
abnormal endotheiiumdependent vasodilation in patients with 
diabetes. These include 1) decreased synthesis of nitric oxide 
by the endothelium, 2) increased inactivation of nitric oxide, 3) 
decreased responsiveness of the nitric oxide-guanylate cyclase 
pathway at the level of the vascular smooth muscle, and 4) 
increased release of vasoconstrictor prostanoids that counter- 
act the vasodilation by nitric oxide. The d&ring vasodilator 
responses in the two diabetic groups (i.e., an attenuated 
response to endogenous but not to exogenous nitric oxide 
donors in insulin-dependent diabetes and an attenuated re- 
sponse to endogenous as well as exogenous nitric oxide donors 
in non-insulin-dependent diahctc\) implicate different mech- 
anisms of vascular dysfunction. Having now completed studies 
in hoth insulin-dependent and non-insulin-dependent diabetes 
with an identical protocol and techniques. we believe that the 
differing responses in these two groups are. in fact. due to 
different pathophysiologic processes and are not simply the 
result of pharmacologic or technical diderences between ex- 
periments. 
Whereas abnormal synthesis or release of ritric oxide by the 
endothelium is the most likely mechanism that could account 
for the data in insulindependent diabetes. the data from the 
non-insulin-dependent diabetic studies implicate increased 
inactivation of nitric oxide or an abnormal response of the 
vascular smooth muscle lo nitric oxide (involving either the 
receptor for guanylate cyclase or subsequent signal transduc- 
tion). Of these. evidence derived from experimental models of 
diabetes suggests that the most likely mechanism is increased 
inactivation of nitric oxide by either oxygen-derived free 
radicals (32) or advanced glycosylation end products (18). 
Oxygen radicals, known to mediate the breakdown of endo- 
thelium-clerived nitric oxide (33). can be produced in diabetes 
by a number of reactions. including glucose autooxidation, 
nonenzymatic protein glycation and cyclooxygenase catalysis 
(32). Indeed. a number of investigators have reported that 
scavengers of oxygen radicals improve endothelium-dependent 
relaxation in diabetic animals both in vitro (34-37) and in vivo 
(38). Furthermore, the attenuated vasodilator response to 
acetylcholine, observed in normal vessels exposed to hypergly- 
cemic medium, is restored by oxygen radical scavengers (39, 
40). Administration of advanced glycosylation end products to 
nondiabetic rats inhibits the vasodilator response to both 
acetylcholine and nitroglycerin in vivo (41). and incubation of 
rat aortic rings with glycosylated human hemoglobin inhibits 
endotheliumdependent relaxation in vitro (42). 
In our experiments in both insulin-dependent and non- 
insulin-dependent diabetes, the diabetic and control groups 
were pretreated with the cyclooxygenase inhibitor aspirin at a 
sufficient dose and duration to block prostanoid formation 
(25). Furthermore, we demonstrated in the present protocol 
that the hemodynamic responses to methacholine, nitroprus- 
side and verapamil in non-insulin-dependent diabetes are 
similar in the presence and absence of cyclooxygenase inhibi- 
tion. Therefore, we think it unlikely that vasoconstrictor pros- 
tanoids have a significant role in the vascular function in 
diabetes mellitus. 
Potential eonfuu~~ders and study limitations. Although the 
non-insulin-dependent diabetic and nondiabetic groups were 
relatively well matched, there was a difference between them 
with respect to body maSS index and triglyceride concentra- 
tions, and, as such, these variables have the potential to 
confound our results. High body mass index is a risk factor for 
non-insulindependent diabetes, and hypert@yceridemia is a 
common finding in this disease; thus, these variables may be 
considered representatives of the diabetic state (as are byper- 
giyemia and hyperinsulinemia) (1). We decided a priori not to 
exclude non-insulin-dependent diabetic candidates on the 
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basis of either criterion. Excluding such diabetic patients would 
encompass only a subset of the non-insulin-dependent diabetic 
group and thus would greatly diminish the generalizability of 
our findings. Nonetheless, subset and univariate regression 
analyses indicate that neither elevated body mass index nor 
hypertriglyceridemia were likely to be responsible for the 
vascular dysfunction that was observed in the subjects with 
non-insulin-dependent diabetes mellitus. 
Sulfonylureas. used as hypoglycemic agents in non-insulin- 
dependent diabetes, have the potential to attenuate vasodila- 
tion by blocking adenosine triphosphate-sensitive potassium 
channels on vascular smooth muscle, thereby inhibiting hyper- 
polarization (43). We attempted to minimize the confounding 
effects of sulfonylurea agents in the design of the study by 
prohibiting their use within 12 h of the experiment. Further- 
more, data from our laboratory indicate that sulfonylureas do 
not inhibit vasodilation to acetylcholine in normal subjects 
(44). rendering sulfonylurea use an unlikely confounder for 
our study. 
The vasodilator response to methacholine chloride in the 
control group, although significantly higher than the response 
in the diabetic group, was relatively modest compared with 
groups of healthy control subjects previously reported (19). 
This difference is the result of the older group required to age 
match the non-insulindependent diabetic group. It is now 
known that endothelium-dependent vasodilation decreases 
with age, and the response in the nondiabetic control subjects 
is appropriate for the average age of that group (45). 
Conelosioos. We demonstrated an abnormality in the ni- 
tric oxide pathway in patients with non-insulin-dependent 
diabetes mellitus and suggest that this may be secondary to 
increased inactivation of nitric oxide or an inability of the 
vascular smooth muscle to respond to nitric oxide. We specu- 
late that loss of the protective properties of nitric oxide may 
contribute to the increased incidence of vascular disease in 
these patients. Understanding the mechanisms by which vas- 
cular function is impaired in non-insulin-dependent diabetes 
may lead to novel therapeutic strategies to reduce cardiovas- 
cular morbidity and mortality in patients with this disease. 
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